Exchange: NYSE
Industry: Pharmaceuticals & Biotechnology
Last Trade: 4:00 PM ET 4/5/2013
Last 10 Quotes:
What's This?
| Fiscal Q4 Ending 12/12 |
Fiscal Q3 Ending 09/12 |
Fiscal Q2 Ending 06/12 |
Fiscal Q1 Ending 03/12 |
Fiscal Q4 Ending 12/11 |
|
Sales/Revenue |
15,068,000 | 13,976,000 | 15,057,000 | 15,405,000 | 16,746,000 |
Cost of Goods Sold (COGS) incl. D&A |
4,347,000 | 3,796,000 | 4,043,000 | 4,394,000 | 4,929,000 |
COGS excluding D&A |
2,452,000 | 2,082,000 | 2,293,000 | 2,142,000 | 2,559,000 |
Depreciation & Amortization Expense |
1,895,000 | 1,714,000 | 1,750,000 | 2,252,000 | 2,370,000 |
Gross Income |
10,721,000 | 10,180,000 | 11,014,000 | 11,011,000 | 11,817,000 |
SG&A Expense |
6,750,000 | 5,733,000 | 5,676,000 | 6,205,000 | 7,674,000 |
Research & Development |
1,999,000 | 1,934,000 | 1,699,000 | 2,072,000 | 2,323,000 |
Other SG&A |
4,751,000 | 3,799,000 | 3,977,000 | 4,133,000 | 5,351,000 |
Other Operating Expense |
0 | 0 | 0 | 0 | -283,000 |
Unusual Expense |
1,657,000 | 1,271,000 | 741,000 | 1,842,000 | 1,202,000 |
Non Operating Income/Expense |
121,000 | 89,000 | 180,000 | -102,000 | -535,000 |
Equity in Affiliates (Pretax) |
NA | 0 | 0 | 0 | 0 |
Interest Expense |
373,000 | 382,000 | 379,000 | 390,000 | 396,000 |
Gross Interest Expense |
385,000 | 382,000 | 379,000 | 390,000 | 396,000 |
Pretax Income |
2,170,000 | 2,991,000 | 4,484,000 | 2,553,000 | 2,293,000 |
Income Tax |
680,000 | -119,000 | 1,290,000 | 750,000 | 800,000 |
Equity in Affiliates |
0 | 0 | 0 | 0 | 0 |
Consolidated Net Income |
1,490,000 | 3,110,000 | 3,194,000 | 1,803,000 | 1,493,000 |
Minority Interest Expense |
6,000 | 6,000 | 7,000 | 9,000 | 11,000 |
Net Income |
1,484,000 | 3,104,000 | 3,187,000 | 1,794,000 | 1,482,000 |
Extraordinaries & Discontinued Operations |
4,831,000 | 104,000 | 66,000 | 0 | -19,000 |
Extra Items & Gain/Loss Sale Of Assets |
4,783,000 | 0 | 0 | 0 | 12,000 |
Cumulative Effect - Accounting Chg |
0 | 0 | 0 | 0 | 0 |
Discontinued Operations |
48,000 | 104,000 | 66,000 | 0 | -31,000 |
Net Income After Extraordinaries |
-3,347,001 | 3,000,000 | 3,120,999 | 1,794,000 | 1,500,999 |
Preferred Dividends |
1,000 | 1,000 | 0 | 0 | 1,000 |
Net Income available to Common |
1,483,000 | 3,103,000 | 3,187,000 | 1,794,000 | 1,481,000 |
Operational EPS |
0.36 | 0.53 | 0.49 | 0.41 | 0.30 |
EPS (basic) |
0.22 | 0.43 | 0.44 | 0.24 | 0.19 |
EBITDA |
5,866,000 | 6,161,000 | 7,088,000 | 7,058,000 | 6,796,000 |
Depreciation & Amortization Expense |
1,895,000 | 1,714,000 | 1,750,000 | 2,252,000 | 2,370,000 |
Common Shares Outstanding |
7,428,235 | 7,508,000 | 7,537,000 | 7,598,000 | 7,870,000 |
Basic Shares Outstanding |
7,341,860 | 7,436,000 | 7,476,000 | 7,537,000 | 7,817,000 |
Diluted Shares Outstanding |
7,428,235 | 7,508,000 | 7,537,000 | 7,598,000 | 7,870,000 |
Diluted EPS after Extraordinary Items |
0.85 | 0.43 | 0.43 | 0.24 | 0.19 |
Discont. Operations Per Share |
0.65 | 0.01 | 0.01 | 0 | -0.00 |
Continued operations EPS |
0.21 | 0.42 | 0.43 | 0.24 | 0.18 |
*Figures in thousands of U.S. Dollars except shares outstanding.
